Role of the distal half of the c-Mpl intracellular domain in control of platelet production by thrombopoietin in vivo.
The cytokine thrombopoietin (TPO) controls the formation of megakaryocytes and platelets from hematopoietic stem cells. TPO exerts its effect through activation of the c-Mpl receptor and of multiple downstream signal transduction pathways. While the membrane-proximal half of the cytoplasmic domain appears to be required for the activation of signaling molecules that drive proliferation, the distal half and activation of the mitogen-activated protein kinase pathway have been implicated in mediating megakaryocyte maturation in vitro. To investigate the contribution of these two regions of c-Mpl and the signaling pathways they direct in mediating the function of TPO in vivo, we used a knock-in (KI) approach to delete the carboxy-terminal 60 amino acids of the c-Mpl receptor intracellular domain. Mice lacking the C-terminal 60 amino acids of c-Mpl (Delta60 mice) have normal platelet and megakaryocyte counts compared to wild-type mice. Furthermore, platelets in the KI mice are functionally normal, indicating that activation of signaling pathways connected to the C-terminal half of the receptor is not required for megakaryocyte differentiation or platelet production. However, Delta60 mice have an impaired response to exogenous TPO stimulation and display slower recovery from myelosuppressive treatment, suggesting that combinatorial signaling by both ends of the receptor intracellular domain is necessary for an appropriate acute response to TPO.
Luoh
S M
SM
Department of Molecular Oncology, Genentech, Inc., South San Francisco, California 94080, USA.
Stefanich
E
E
Solar
G
G
Steinmetz
H
H
Lipari
T
T
Pestina
T I
TI
Jackson
C W
CW
de Sauvage
F J
FJ
D000818:Animals; D001772:Blood Cell Count; D001792:Blood Platelets / Q000166:cytology* / Q000187:drug effects / Q000502:physiology; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D005091:Exons / Q000235:genetics; D005340:Fibrinogen / Q000378:metabolism; D006410:Hematopoiesis; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects; D008533:Megakaryocytes / Q000166:cytology / Q000187:drug effects; D051379:Mice; D008822:Mice, Transgenic; D009363:Neoplasm Proteins; D010766:Phosphorylation / Q000187:drug effects; D019000:Phosphotyrosine / Q000378:metabolism; D015539:Platelet Activation; D011003:Ploidies; D011518:Proto-Oncogene Proteins / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D018121:Receptors, Cytokine / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D053628:Receptors, Thrombopoietin; D017384:Sequence Deletion / Q000235:genetics; D015398:Signal Transduction / Q000187:drug effects; D013926:Thrombopoietin / Q000494:pharmacology*; D013997:Time Factors
D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; C082218:MPL protein, human; D019000:Phosphotyrosine; D005340:Fibrinogen; D013926:Thrombopoietin